By THE ASSOCIATED PRESS
The Canadian drug maker is dealing with three federal inquiries into its accounting and business practices, and a huge plunge in its stock price.
Published: April 30, 2016 at 12:00AM
from NYT Business Day http://ift.tt/1VXXoC2
from WordPress http://ift.tt/1royxtQ
via Hadi Aboukhater
No comments:
Post a Comment